BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...

The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC) with Olvi-Vec, ...

Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients ... The Company’s development ...

It often responds initially to chemotherapy but is the most common breast cancer to recur. When it recurs, triple-negative breast cancer portrays chemotherapy resistance, making it less responsive and ...

Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution ...

👑 Easy-to-use and powerful NLP and LLM library with 🤗 Awesome model zoo, supporting wide-range of NLP tasks from research to industrial applications, including 🗂Text Classification, 🔍 Neural ...

Taipei City Government has established 11 visitor information centers in Taipei. The services at each center are tailored to the specific attractions in the vicinity. In addition to counter help, the ...

NaV 1.7 inhibition pain treatment, Halneuron®, Phase 2b study for chemotherapy-induced neuropathic ... external partnership activities. For more information, please visit www.dwtx.com.

Nearly two months after the Princess of Wales announced she had completed her chemotherapy treatment—about six months after sharing her cancer diagnosis—the Prince of Wales opened up about his ...

Kate Middleton is in her comeback era. The Princess of Wales, 42, is working out again after completing chemotherapy in September, according to royal expert Robert Jobson. “From what I ...